Prejudice to the Brazil Pharma climbs 26 times in the quarter

The Brazil Pharma recorded net loss of R $ 185,29 million in the first quarter of this year. In the same period last year, the net loss was $ 6.98 million.
According to the profit and loss account, available on the website of the Securities and Exchange Commission (CVM), the company's net revenue was r $ 853,1 million in the first quarter, 13.9% higher than the r $ 748,8 million net revenue in the same period in 2013.
The cost of the company's sales in the first quarter reached r $ 678,2 million, against r $ 515,9 million in the year-ago quarter, a high of 31.4%.
The gross profit of Brazil Pharma in the first quarter fell 24.9 percent in the first quarter of this year, to $ 174,8 million. Operating expenditure increased 56.3% to r $ 346,2 million. The operating loss totaled r $ 171,4 million, compared with operating profit of $ 11.3 million in the first quarter of 2013.
Net financial expenses between January and March totaled r $ 24.9 million, up 32% over the same period of the previous year.
Padilha
The Brazil Pharma announced that Davie Padilha Executive took over today as Vice President of finance and strategy of the company, as well as the position of Director of investor relations.
Padilha is Corporate Director of loss prevention and risks in Grupo Pão de Açúcar, having served as CFO and investor relations at Via retail.